Impact BioMedical, Inc. Market Cap ($45.54 Million)
Market Cap & Net Worth: Impact BioMedical, Inc. (IBO)
Impact BioMedical, Inc. market cap. Impact BioMedical, Inc. (NYSE MKT:IBO) has a market capitalization of $45.54 Million ($45.54 Million) as of October 31, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #22080 globally and #4917 in its home market, demonstrating a 4.89% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Impact BioMedical, Inc.'s stock price $0.44 by its total outstanding shares 104621231 (104.62 Million).
Impact BioMedical, Inc. Market Cap History (2017–2026)
Impact BioMedical, Inc. market cap history from 2017 to 2026. Data shows change from $2.35 Billion to $45.54 Million (-38.01% CAGR). Check current stock price of Impact BioMedical, Inc. for real-time trading data and today's change.
Impact BioMedical, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Impact BioMedical, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Impact BioMedical, Inc. (IBO) cash conversion ratio for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
65.08x
Impact BioMedical, Inc.'s market cap is 65.08 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $13.60 Million | $50.00K | -$3.87 Million | 272.02x | N/A |
| 2022 | $40.65 Billion | $50.00K | -$7.05 Million | 812906.96x | N/A |
| 2024 | $151.70 Million | $2.33 Million | -$2.05 Million | 65.08x | N/A |
Competitor Companies of IBO by Market Capitalization
Companies near Impact BioMedical, Inc. in the global market cap rankings as of October 31, 2026. See Impact BioMedical, Inc. (IBO) net asset quality to understand what proportion of total assets are financed by equity.
Key companies related to Impact BioMedical, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Impact BioMedical, Inc. (2017–2026)
Market capitalization of Impact BioMedical, Inc. from 2017 to today. Between 2017 and today, Impact BioMedical, Inc.'s market cap moved from $2.35 Billion to $ 45.54 Million, with a yearly change of -38.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $45.54 Million | -35.80% |
| 2025 | $70.93 Million | -53.24% |
| 2024 | $151.70 Million | -99.63% |
| 2022 | $40.65 Billion | +298746.15% |
| 2021 | $13.60 Million | -99.48% |
| 2020 | $2.60 Billion | +5.02% |
| 2019 | $2.47 Billion | 0.00% |
| 2018 | $2.47 Billion | +5.52% |
| 2017 | $2.35 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Impact BioMedical, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $45.54 Million USD |
| MoneyControl | $45.54 Million USD |
| MarketWatch | $45.54 Million USD |
| marketcap.company | $45.54 Million USD |
| Reuters | $45.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Impact BioMedical, Inc.
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application … Read more